Aclarion, Inc. (ACON) Stock

Aclarion, Inc. (ACON) is a Healthcare stock trading at $2.42 (as of 2026-09-02), with a market capitalization of $5.96M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Understand Aclarion, Inc.: how it makes money

Aclarion develops software that processes magnetic resonance spectroscopy data to identify biomarkers of degenerative back pain, sold to imaging centers and pain clinics. The business is in an early commercial phase: revenue is negligible today, and the entire model hinges on getting its MRS post-processing suite adopted into routine clinical pain-diagnosis workflows.

Every dollar of future profit depends on a single software product (NOCISCAN-LS) clearing clinical adoption hurdles in pain imaging; until that happens, the company has no revenue engine and burns cash on R&D and go-to-market.

Business quality (Unprofitable): Unprofitable and effectively pre-revenue. With operating margin at negative 11503 percent and gross margin at 33 percent, the company is in a heavy cash-burn phase with no demonstrated path to self-funding yet.

Bull case

  • Software margins improve with scale: Gross margin sits at 33 percent on a tiny revenue base, which for a post-processing software product suggests early-stage development and licensing costs are still front-loaded. Once the NOCICALC-LS and NOCIGRAM-LS suite is deployed at more imaging sites, marginal cost per additional scan processed is low, leaving room for margin expansion.

Bear case

  • Cash burn has no visible floor: Operating margin of negative 11503 percent means the company spends roughly 115 times what it earns in operating expenses. With revenue rounding to zero, there is no internal cash flow to limit dilution, and investors are funding purely on future-adoption hope.
Valuation — source: SEC EDGAR (first-party)
Price$2.42
Market Cap$5.96M
Price / Book0.35
Price / Sales71.13
FCF Yield-120.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$75730.00
Net Margin-9551.9%
Revenue Growth (YoY)30.5%
EPS Growth (YoY)-59.3%
FCF Growth (YoY)21.1%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.71 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Healthcare Services)24.6
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderOSAIC HOLDINGS, INC. ($114269.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryHealthcare Services
CEOBrent Ness
Employees5
CountryUS
IPO Date2023-02-27

Related Companies (Healthcare Services; 8 comparable companies)

  • Sera Prognostics, Inc. (SERA)
  • Advanced Biomed Inc. Common Stock (ADVB)
  • Cardio Diagnostics Holdings, Inc. (CDIO)
  • OneMedNet Corporation (ONMD)
  • Q/C Technologies, Inc. (QCLS)
  • VolitionRx Limited (VNRX)
  • iSpecimen Inc. (ISPC)
  • 20/20 Biolabs, Inc. Common Stock (AIDX)
ACON earnings history · ACON institutional & insider holders · ACON KPIs & operating metrics · ACON financials · ACON investor presentations & press releases · ACON SEC filings · ACON peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.